144 related articles for article (PubMed ID: 23645657)
1. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).
Shoji J; Lew SQ
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645657
[TBL] [Abstract][Full Text] [Related]
2. Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.
Bartel C; Obermüller N; Rummel MJ; Geiger H; Hauser IA
Clin Nephrol; 2008 Apr; 69(4):285-9. PubMed ID: 18397703
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
Quinquenel A; Willekens C; Dupuis J; Royer B; Ysebaert L; De Guibert S; Michallet AS; Feugier P; Guieze R; Levy V; Delmer A
Am J Hematol; 2015 Mar; 90(3):204-7. PubMed ID: 25428829
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
Friedberg JW
Leuk Lymphoma; 2009 Sep; 50(9):1399-400. PubMed ID: 19811324
[No Abstract] [Full Text] [Related]
6. Huge kidneys in a patient with chronic lymphocytic leukaemia.
Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
[No Abstract] [Full Text] [Related]
7. [Chronic lymphocytic leukemia accompanied by renal failure].
Dzhumbaeva BT; Biriukova LS; Gemdzhian EG; Kravchenko SK; Melikian AL; Roshtina LS
Ter Arkh; 2014; 86(12):37-41. PubMed ID: 25804038
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Seipelt G; Böhme A; Koschmieder S; Hoelzer D
Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
Vacirca JL; Acs PI; Tabbara IA; Rosen PJ; Lee P; Lynam E
Ann Hematol; 2014 Mar; 93(3):403-9. PubMed ID: 23955074
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
Iannitto E; Morabito F; Mancuso S; Gentile M; Montanini A; Augello A; Bongarzoni V; D'Arco A; Di Renzo N; Fazzi R; Franco G; Marasca R; Mulè A; Musso M; Musto P; Pennese E; Piccin A; Rota-Scalabrini D; Visani G; Rigacci L
Br J Haematol; 2011 May; 153(3):351-7. PubMed ID: 21371003
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
[No Abstract] [Full Text] [Related]
15. Making advances in first-line chronic lymphocytic leukemia treatment.
Wierda WG
J Clin Oncol; 2012 Sep; 30(26):3162-4. PubMed ID: 22869876
[No Abstract] [Full Text] [Related]
16. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
17. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
[No Abstract] [Full Text] [Related]
18. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
[TBL] [Abstract][Full Text] [Related]
19. Novel agents for chronic lymphocytic leukemia.
Wu M; Akinleye A; Zhu X
J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
